BioLargo, Inc.’s CEO Discusses Business Milestones and FDA Progress with Uptick Newswire’s Stock Day Podcast
PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dennis Calvert, CEO of BioLargo, Inc. (OTCQB:BLGO), recently spoke with Stock Day Podcast’s Everett Jolly to update listeners on the company’s recent milestones.
Jolly started out the interview highlighting that BioLargo’s odor and VOC control products are set to do over $1 million in revenue in 2018.
“We launched the product about two years ago into the municipal waste handling industry,” Calvert explains to Uptick. “It took us about a year to get our foothold in the market and over the past six months, we signed national purchasing agreements with four of the top municipal waste handling companies in the country and have enjoyed 100% regional adoption with those accounts in Southern California, so the market is finally catching on that ours is a great product backed by great service. We are also servicing early adopters in the waste water treatment industry and new industries are just getting started as well. We have also transitioned from being a tech shop to a solutions provider, adding engineering, system design, installation, maintenance and service. We have only scratched the surface of the global opportunity for CupriDyne Clean.”
Jolly then shifted the interview to talk about Clyra Medical Technologies, Inc., the BioLargo subsidiary that uses innovative patent protected chemistry in advanced wound care. Calvert discussed the progress of its advanced wound care products under its subsidiary Clyra Medical Technologies, and its recent 510 (k) application with the FDA.
In a follow-up to the interview, Calvert expanded on their recent trip to Washington, DC to meet with the FDA about the company’s pending application. “In our meeting with FDA representatives last week, we were able to clarify the data requirements and the appropriate pathway to success for our application. The first series of questions asked of our team relates to labeling, shelf-life, and composition, and we think that request and the answers are straight forward. The more important request they made was that we conduct a short-term live animal study which requires a small period of work and money to accomplish. We believe the time frame to meet these requests is manageable within the next few months, and that the outcome will ultimately result in FDA clearance of the product.”
Jolly also asked Dennis about BioLargo Water’s AOS (Advanced Oxidation System), which is a technological breakthrough in water and wastewater treatment and has the potential to provide effective and cost-efficient elimination of pathogens and hard-to-treat organics from wastewater. Calvert said the product is nearing commercialization and is even currently part of several pre-commercial pilot projects in real world industrial settings. He also went on to explain the exciting independent 3rd-party validation of the high-value use of the AOS for managing micropollutants and other hard-to-treat contaminants for the wastewater industry.
“We have major projects that all focus on taking the system into the field to work with real clients to prove out its real economic value,” Calvert explained. “It’s the final piece of making that technology ready for market. We think it’s pretty exciting.”
To hear the entire interview with Dennis Calvert, click the Stock Day podcast link (https://upticknewswire.com/featured-interview-ceo-dennis-calvert-of-biolargo-inc-otcqb-blgo-10/).
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.